{"url_path":"/sec/lnai/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1527728/0001731122-26-000749-index.html","accession_number":"0001731122-26-000749","cik":"0001527728","ticker":"LNAI","issuer_name":"Lunai Bioworks Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527728/0001731122-26-000749-index.html","primary_entity_key":"0001527728","primary_entity_name":"Lunai Bioworks Inc."},"word_count":207,"has_tables":true,"body_markdown":"**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**\n\n \n\nOn March 24, 2026, the Company\nentered into separate Debt Exchange Agreements with three holders of its secured promissory notes (the “Holders”), pursuant\nto which the Company issued an aggregate of 3,909,293 shares of common stock and warrants to purchase up to 1,433,621 shares of common\nstock at an exercise price of $0.21 per share, in exchange for the cancellation of $828,770 of outstanding principal and accrued interest\nunder the secured promissory notes held by the Holders. The shares of common stock and warrants (and the shares of common stock issuable\nupon exercise of the warrants) were issued in reliance upon the exemptions from the registration requirements of the Securities Act of\n1933, as amended (the “Securities Act”), provided by Section 3(a)(9) thereof (relating to exchanges with existing security\nholders for no consideration paid for soliciting the exchange) and Section 4(a)(2) thereof (relating to transactions not involving a public\noffering). The Company filed a Current Report on Form 8-K disclosing these transactions on March 30, 2026.\n\n \n\n(c) **Issuer Purchases of Equity\nSecurities.** None. The Company did not repurchase any shares of its common stock or other equity securities during the three months\nended March 31, 2026."}